Why Mass-Balance Materials Are Preferred Over Bio-Based for Pharmaceutical Manufacturing

Sustainability has become an important consideration in pharmaceutical manufacturing, particularly as organizations work to reduce Scope 3 emissions associated with purchased materials. At the same time, the industry operates under strict regulatory and quality expectations that limit the types of material changes that can be introduced without significant validation effort.

Within this context, three material approaches are commonly discussed: bio-based materials, mass-balance materials, and circular feedstocks. While each contributes to broader sustainability goals, their suitability for regulated pharmaceutical applications differs significantly.

Regulatory Stability as a Primary Requirement

Pharmaceutical manufacturing systems are qualified based on defined material specifications, performance characteristics, and safety profiles. Once validated, any change to material composition, formulation, or production pathway may require reassessment of extractables, leachables, mechanical performance, and biological safety.

As a result, sustainability strategies in this sector must prioritize material equivalence and continuity. Approaches that introduce chemically distinct polymers or new production routes inherently carry greater regulatory and operational risk.

Bio-Based Materials

Bio-based polymers are produced entirely or predominantly from renewable biological sources such as sugarcane, corn, or other plant-derived feedstocks. These materials are typically manufactured in separate, dedicated production streams from fossil-based polymers.

From a pharmaceutical manufacturing perspective, bio-based materials present several structural limitations:

• Polymer chemistry and molecular structure often differ from established fossil-based grades
• Pharmaceutical-grade availability is limited across many material classes
• Extractables and leachables profiles frequently require new characterization
• Long-term supply stability depends on agricultural feedstocks and regional production capacity
• Adoption can trigger requalification, documentation updates, and change control processes

Bio-based polymers play an important role in consumer and industrial markets, but their integration into GMP single-use systems remains constrained by regulatory and validation considerations.

Mass-Balance Materials

Mass-balance materials use renewable or circular feedstocks, such as bio-naphtha derived from used cooking oil (UCO), that are introduced into existing chemical production infrastructure. Renewable and fossil feedstocks are processed together, while the renewable share is measured, tracked, and allocated through audited accounting systems.

Under mass-balance methodology:

• Polymerization occurs using the same equipment, conditions, and formulations as fossil-based materials
• The resulting polymers are chemically identical to conventional grades
• Renewable attribution is verified through third-party certification such as ISCC PLUS
• Material specifications, safety profiles, and performance characteristics remain unchanged

Because the material itself does not change, mass-balance polymers maintain full continuity with previously validated systems. Sustainability is achieved through verified feedstock substitution, not reformulation.

Circular Feedstocks

Circular feedstocks are derived from recovered waste materials, often through chemical recycling technologies such as pyrolysis. These processes convert plastic waste into hydrocarbon feedstocks that can reenter polymer production streams.

In pharmaceutical applications, circular feedstocks are most commonly introduced via mass-balance systems, ensuring chemical equivalence while attributing circular content. While this approach is technically viable, adoption in regulated environments remains limited by availability, regional infrastructure, and evolving regulatory acceptance.

Circular feedstocks represent a growing long-term opportunity, particularly as recycling technologies mature and regulatory frameworks continue to develop.

Comparative Alignment with Pharmaceutical Manufacturing

This comparison highlights why mass-balance materials are increasingly adopted in pharmaceutical supply chains where stability, compliance, and scalability are non-negotiable.

Verification and Credibility of Sustainability Claims

Mass-balance systems rely on audited chain-of-custody frameworks that prevent double-counting and ensure traceability. Certification schemes such as ISCC PLUS require:

• Verified sourcing of renewable or circular feedstocks
• Documented material flows through production and conversion steps
• Independent auditing of allocation methods

This structure allows pharmaceutical manufacturers to rely on sustainability claims that are transparent, auditable, and aligned with ESG and procurement expectations.

Practical Implications for Pharmaceutical Manufacturers

Mass-balance materials enable organizations to reduce fossil feedstock reliance while maintaining:

• Existing material qualifications
• Established supplier relationships
• Consistent performance across global sites
• Predictable regulatory documentation

For regulated manufacturing environments, this approach aligns sustainability progress with operational continuity rather than introducing parallel material strategies.

Conclusion

Among the available material pathways, mass-balance materials currently provide the most practical alignment with pharmaceutical manufacturing requirements. They deliver verified sustainability improvements while preserving material equivalence, regulatory stability, and supply reliability.

Bio-based and circular materials continue to play important roles in broader sustainability strategies. However, for GMP single-use systems operating at global scale, mass balance offers a measured, scalable, and low-risk pathway to reducing environmental impact without compromising quality or compliance.